Ignite Creation Date:
2024-05-05 @ 11:22 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00001561
Status:
COMPLETED
Last Update Posted:
2007-09-24
First Post:
1999-11-03
Brief Title:
Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation
Sponsor:
National Cancer Institute NCI
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation
Status:
COMPLETED
Status Verified Date:
2005-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Both patients and marrow donors are treated on Regimen A patients then proceed to Regimen B The following acronyms are used
ABM Allogeneic Bone Marrow
BU Busulfan NSC-750
CF Leucovorin calcium NSC-3590
CTX Cyclophosphamide NSC-26271
G-CSF Granulocyte Colony-Stimulating Factor source not specified
GM-CSF Granulocyte-Macrophage Colony-Stimulating Factor HoechstImmunex NSC-613795
GVHD Graft-vs-Host Disease
Mesna Mercaptoethane sulfonate NSC-113891
MTX Methotrexate NSC-740
PP Unconjugated Myeloma Immunoglobulin plasma paraprotein NSC-684150
PP-KLH Myeloma immunoglobulin plasma paraprotein vaccine NSC-678327 with keyhole limpet hemocyanin
TBI Total-Body Irradiation
TSPA Thiotepa NSC-6396
Regimen A Donor and Patient Vaccine Therapy with Immunoadjuvant PP-KLH individual myeloma immunoglobulin plasma paraprotein vaccine prepared from recipients plasma paraprotein and conjugated with KLH and PP with GM-CSF
Regimen B Patient Myeloablative Radiotherapy and 2-Drug Combination Chemotherapy or 2-Drug Combination Myeloablative Chemotherapy followed by Hematopoietic Rescue with Growth Factor Support and GVHD Prophylaxis followed by Vaccine Therapy with Immunoadjuvant TBI and CTXTSPA or BUCTX followed by ABM with G-CSF and CYSP MTXCF followed by PP-KLH with GM-CSF
ABM Allogeneic Bone Marrow
BU Busulfan NSC-750
CF Leucovorin calcium NSC-3590
CTX Cyclophosphamide NSC-26271
G-CSF Granulocyte Colony-Stimulating Factor source not specified
GM-CSF Granulocyte-Macrophage Colony-Stimulating Factor HoechstImmunex NSC-613795
GVHD Graft-vs-Host Disease
Mesna Mercaptoethane sulfonate NSC-113891
MTX Methotrexate NSC-740
PP Unconjugated Myeloma Immunoglobulin plasma paraprotein NSC-684150
PP-KLH Myeloma immunoglobulin plasma paraprotein vaccine NSC-678327 with keyhole limpet hemocyanin
TBI Total-Body Irradiation
TSPA Thiotepa NSC-6396
Regimen A Donor and Patient Vaccine Therapy with Immunoadjuvant PP-KLH individual myeloma immunoglobulin plasma paraprotein vaccine prepared from recipients plasma paraprotein and conjugated with KLH and PP with GM-CSF
Regimen B Patient Myeloablative Radiotherapy and 2-Drug Combination Chemotherapy or 2-Drug Combination Myeloablative Chemotherapy followed by Hematopoietic Rescue with Growth Factor Support and GVHD Prophylaxis followed by Vaccine Therapy with Immunoadjuvant TBI and CTXTSPA or BUCTX followed by ABM with G-CSF and CYSP MTXCF followed by PP-KLH with GM-CSF
Detailed Description:
Multiple Myeloma remains a largely incurable disease with current therapy Allogeneic bone marrow transplantation provides an opportunity to add the potential antitumor effect of marrow grafts to those of high dose chemotherapy One potential strategy for enhancing a graft vs tumor effect without aggravating graft vs host disease would be to selectively target an immune response against a defined tumor-specific antigen The idiotype of the rearranged immunoglobulin gene product of a myeloma can serve as a unique tumor-specific antigen for vaccine development We are testing the hypothesis that tumor antigen-specific immunity can be adoptively transferred to BMT recipients by active immunization of marrow transplant donors with purified myeloma idiotype protein conjugated to a carrier protein KLH and administered with GM-CSF as an immunological adjuvant
Patients under age 60 with an HLA-matched sibling donor with minimal prior treatment defined by less than six months prior chemotherapy and who are in a minimal residual disease state prior to allogeneic BMT as defined by the achievement of at least a PR are eligible HLA matched sibling donors receive a series of three vaccinations during an eight week period prior to bone marrow harvest Recipients concurrently receive vaccinations pre-BMT as well as three booster vaccinations at weeks 12 16 and 24 post-BMT Id-KLH 05 mg is administered sc GM-CSF 250 microgramsm2 is administered sc locally with the vaccine on the day of vaccination and for the three consecutive days following vaccination The objective of this protocol is to induce cellular and humoral immunity in marrow transplant donors and recipients against the unique idiotype expressed by the recipients myeloma
Patients under age 60 with an HLA-matched sibling donor with minimal prior treatment defined by less than six months prior chemotherapy and who are in a minimal residual disease state prior to allogeneic BMT as defined by the achievement of at least a PR are eligible HLA matched sibling donors receive a series of three vaccinations during an eight week period prior to bone marrow harvest Recipients concurrently receive vaccinations pre-BMT as well as three booster vaccinations at weeks 12 16 and 24 post-BMT Id-KLH 05 mg is administered sc GM-CSF 250 microgramsm2 is administered sc locally with the vaccine on the day of vaccination and for the three consecutive days following vaccination The objective of this protocol is to induce cellular and humoral immunity in marrow transplant donors and recipients against the unique idiotype expressed by the recipients myeloma
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 97-C-0030 | None | None | None |